Key Facts and Data Points

  • Celebration Date: 7 March 2026 (Jan Aushadhi Diwas)\
  • Theme: "Janaushadhi Sasti Bhi, Bharosemand Bhi, Sehat Ki Baat, Bachat Ke Saath"\
  • Administering Body: Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers\
  • Scheme Origin: Launched as Jan Aushadhi Scheme in 2008; re‑branded as Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in 2016\
  • Product Portfolio (2026): ~2,110 medicines & 315 surgical items across 29 therapeutic categories (including anti‑cancer, cardiovascular, anti‑diabetic)\
  • Price Advantage: Generic medicines priced 50‑90% lower than branded equivalents\
  • Quality Assurance: WHO‑GMP certified manufacturers; testing in NABL‑accredited labs\
  • Digital Tool: Jan Aushadhi Sugam App – geo‑location of Kendras, price comparison, stock status\
  • Special Initiatives:\
  • Janaushadhi Suvidha Sanitary Napkins (Rs 1 per pad)\
  • Franchise incentives up to Rs 2 lakh for women, SC/ST, Divyangjan, ex‑servicemen\
  • Kendra Network (early 2026): >18,000 Kendras; target >25,000 by March 2027\
  • Innovative Locations (Jan 2026): 116 Kendras at railway stations; many within government hospitals\
  • Rural Outreach: Leveraging Primary Agricultural Credit Societies (PACS) for Kendra set‑up\
  • Economic Impact: Estimated citizen savings of Rs 38,000 crore by June 2025\

Background and Context

  • India’s health expenditure is heavily out‑of‑pocket (≈62% of total health spend, 2022). High drug prices exacerbate financial distress, especially for the poor.\
  • The Jan Aushadhi Scheme was introduced to create a parallel supply chain of affordable, quality‑assured generics.\
  • PMBJP aligns with the National Health Policy 2017 and Ayushman Bharat objectives of reducing catastrophic health expenditure and achieving universal health coverage (UHC).\

Significance for India / Governance / Policy

  • Financial Protection: By offering medicines at 50‑90% lower prices, the scheme directly reduces out‑of‑pocket (OOP) spending, a key determinant of health‑related poverty.\
  • Access & Equity: Franchise model and incentives promote entrepreneurship among marginalized groups, enhancing rural and underserved area coverage.\
  • Digital Governance: The Sugam App exemplifies e‑governance, improving transparency, price comparison, and consumer awareness.\
  • Public‑Private Synergy: Quality control through WHO‑GMP and NABL ensures that cost‑effectiveness does not compromise safety, building public trust.\
  • Strategic Integration: Placement of Kendras in railway stations and hospitals leverages existing footfall, ensuring last‑mile access.\

Related Constitutional / Legal Provisions

  • Article 21 (Right to Life) – interpreted by the Supreme Court to include the right to health.\
  • National Health Policy 2017 – emphasizes affordable medicines and reduction of OOP expenditure.\
  • Drugs (Prices Control) Order, 2013 – complements PMBJP by regulating prices of essential medicines.\
  • Pharmaceuticals and Medical Devices Bureau of India (PMBI) – statutory body overseeing implementation.\

Exam‑Relevant Angles

  • Prelims: Factual data – launch year, number of medicines, price reduction, ministry, target Kendra count.\
  • Mains: Analyse impact on UHC, fiscal implications, role of digital tools, challenges in quality assurance, comparison with other countries’ generic drug policies.\

Prepared for UPSC aspirants – concise, exam‑focused.